Examiner.com
Lynda Seminara
Dimebon is a promising medication for Alzheimer's disease, which differs from the drugs commonly used for this condition.
This 25-year-old Russian antihistamine has been successful for stabilizing Alzheimer's disease. The difference it has been making is "the biggest ever seen in Alzheimer's disease," according to David T. Hung, MD, President and CEO of the the US firm developing Dimebon.
Dimebon is just one study away from FDA approval. The Phase III clinical trial is currently enrolling patients. There are 25 participating sites in the United States, including one in Norristown, PA.
Here's more about this investigational trial.....read the whole article
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
Columbus trivia
4 years ago
1 comment:
Clinical studies like this and others are the best chances we have for fighting Alzheimer's disease. It really is important for patients and families affected by this disease to consider participation in a clinical study. Another one is the ICARA study (www.icarastudy.com). Its goal is to explore if an investigational drug called bapineuzumab can help slow the progression of Alzheimer's.
Post a Comment